Literature DB >> 1607699

Persistence of measles antibody after revaccination.

L E Markowitz1, P Albrecht, W A Orenstein, S M Lett, T J Pugliese, D Farrell.   

Abstract

To evaluate persistence of measles antibody after revaccination, antibody levels were measured 6 years after revaccination of 40 hemagglutination-inhibition (HAI) antibody-negative students who had participated in a serosurvey in Massachusetts. Twelve subjects who had been HAI antibody-positive and were not revaccinated were included as a comparison group. Before revaccination, 7 revaccinees had no detectable plaque reduction neutralization (PRN) antibody (group 1) and 33 had low levels of PRN antibody (group 2). Three weeks after revaccination, all in group 1 and 30 (90%) of 33 in group 2 had developed a fourfold or greater rise in PRN antibody. Six years after revaccination, all subjects had PRN-detectable antibody. However, 12 in group 2 (36%) had antibody titers less than or equal to 1:120 compared with none in group 1 (P less than .01). Persons without PRN antibody will respond to revaccination and maintain protective antibody titers. In contrast, persons with low levels of PRN antibody may respond initially to revaccination, but their antibody titers may fall again to low levels.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1607699     DOI: 10.1093/infdis/166.1.205

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  17 in total

1.  Immunity to measles in the Croatian population.

Authors:  Berislav Borcić; Renata Mazuran; Bernard Kaić
Journal:  Eur J Epidemiol       Date:  2003       Impact factor: 8.082

2.  The Reemergence of Measles.

Authors:  C L Abad; N Safdar
Journal:  Curr Infect Dis Rep       Date:  2015-12       Impact factor: 3.725

3.  MMR Vaccine: When Is the Right Time for the Second Dose?

Authors:  Oscar R Herrera; Terrika A Thornton; Richard A Helms; Stephan L Foster
Journal:  J Pediatr Pharmacol Ther       Date:  2015 Mar-Apr

4.  Economic benefits of a routine second dose of combined measles, mumps and rubella vaccine in Canada.

Authors:  M Rivière; R Tretiak; C Levinton; C Fitzsimon; C Leclerc
Journal:  Can J Infect Dis       Date:  1997-09

5.  Measles immunity and response to revaccination among secondary school children in Cumbria.

Authors:  N Calvert; F Cutts; R Irving; D Brown; J Marsh; E Miller
Journal:  Epidemiol Infect       Date:  1996-02       Impact factor: 2.451

6.  Safety and immunogenicity of early measles vaccination in children born to HIV-infected mothers in the United States: results of Pediatric AIDS Clinical Trials Group (PACTG) protocol 225.

Authors:  Sulachni Chandwani; Judy Beeler; Hong Li; Susette Audet; Betsy Smith; John Moye; David Nalin; Keith Krasinski
Journal:  J Infect Dis       Date:  2011-07       Impact factor: 5.226

7.  Measles vaccination policy.

Authors:  B G Williams; F T Cutts; C Dye
Journal:  Epidemiol Infect       Date:  1995-12       Impact factor: 2.451

8.  Cross-sectional surveys of measles antibodies in the Jiangsu Province of China from 2008 to 2010: the effect of high coverage with two doses of measles vaccine among children.

Authors:  Yuanbao Liu; Peishan Lu; Ying Hu; Zhiguo Wang; Xiuying Deng; Fubao Ma; Hong Tao; Chengmei Jia; Xiaoyan Ding; Haitao Yang; Pei Liu; Jie Min
Journal:  PLoS One       Date:  2013-06-25       Impact factor: 3.240

9.  A large observational study to concurrently assess persistence of measles specific B-cell and T-cell immunity in individuals following two doses of MMR vaccine.

Authors:  Iana H Haralambieva; Inna G Ovsyannikova; Megan O'Byrne; V Shane Pankratz; Robert M Jacobson; Gregory A Poland
Journal:  Vaccine       Date:  2011-05-01       Impact factor: 3.641

Review 10.  Active immunization in the United States: developments over the past decade.

Authors:  P H Dennehy
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.